Anti-Fibroblast activation protein, alpha antibody is a rabbit polyclonal antibody that is used to detect Fibroblast activation protein, alpha in IHC-P, Western blot. Suitable for Human samples.
- Detects endogenous levels of fibroblast activation protein alpha (FAPα)
- The immunogen used to produce this product has 92% homology with Mouse DPPIV/CD26
- Cited in over 130 publications
pH: 7
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 - 1/1000 | Notes Please see WB protocol details in the image legend. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 - 1/100 | Notes Antigen retrieval: Microwave method - put the slice into 10 mmol/L citrate buffer (pH 6.0), microwave high temperature for 5 minutes, and then medium temperature for 15 minutes. Primary antibody incubation: 1 hour at 37°C Secondary antibody: Poly-HRP-Anti Mouse/Rabbit IgG, 50 μL for 30 minutes. DAB reagent. |
Select an associated product type
The protein expressed by the FAP gene is a cell surface glycoprotein serine protease involved in the degradation of the extracellular matrix (ECM) and various cellular processes such as tissue remodeling, fibrosis, wound healing, inflammation, and tumor growth. It exists in both plasma membrane-bound and soluble forms, exhibiting post-proline cleaving endopeptidase activity, specifically targeting Ala/Ser-Gly-Pro-Ser/Asn/Ala sequences in substrates like alpha-2-antiplasmin SERPINF2 and SPRY2. FAP protein degrades gelatin and heat-denatured type I collagen but not native type I and IV collagens, nor vitronectin, tenascin, laminin, fibronectin, fibrin, or casein. It also has dipeptidyl peptidase activity, hydrolyzing prolyl bonds when the penultimate residue is proline, with a preference for sequences such as Ala-Pro and Gly-Pro. It acts on natural neuropeptides like neuropeptide Y, peptide YY, substance P, and brain natriuretic peptide 32. In its membrane form, in association with DPP4, PLAUR, or integrins, FAP is involved in pericellular ECM proteolysis, promoting cell adhesion, migration, invasion, and plays roles in development, wound healing, and cell invasiveness in malignant melanoma. It supports tumor progression by facilitating angiogenesis, collagen degradation, apoptosis, and reducing immune response. Additionally, it promotes glioma cell invasion by degrading brevican and functions as a tumor suppressor in melanocytic cells by regulating cell proliferation and survival independently of its serine protease activity. This supplementary information is collated from multiple sources and compiled automatically.
Prolyl endopeptidase FAP, 170 kDa melanoma membrane-bound gelatinase, Dipeptidyl peptidase FAP, Fibroblast activation protein alpha, Gelatine degradation protease FAP, Integral membrane serine protease, Post-proline cleaving enzyme, Serine integral membrane protease, Surface-expressed protease, FAPalpha, SIMP, Seprase, FAP
Anti-Fibroblast activation protein, alpha antibody is a rabbit polyclonal antibody that is used to detect Fibroblast activation protein, alpha in IHC-P, Western blot. Suitable for Human samples.
- Detects endogenous levels of fibroblast activation protein alpha (FAPα)
- The immunogen used to produce this product has 92% homology with Mouse DPPIV/CD26
- Cited in over 130 publications
pH: 7
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
ab53066 detects endogenous levels of total Fibroblast activation protein, alpha. Please note the immunogen used to produce this product has 92% homology with Mouse DPPIV/CD26.
ab53066 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Anti-Fibroblast activation protein, alpha (FAP) antibody (ab53066) is a rabbit polyclonal antibody and is validated for use in IHC-P, WB in human, mouse, rabbit samples.
Anti-Fibroblast activation protein, alpha antibody (ab53066) has been cited over 134 times in peer reviewed journals and is trusted by the scientific community.
Abcam's high quality validation processes ensure Anti-Fibroblast activation protein, alpha antibody (ab53066) has high sensitivity and specificity.
Anti-Fibroblast activation protein, alpha antibody (ab53066) has 13 independent reviews from customers.
Anti-Fibroblast activation protein, alpha antibody (ab53066) specifically detects Fibroblast activation protein, alpha (UniProt ID: Q12884; Molecular weight: 88kDa) and is sold in 100 µg selling sizes.
Fibroblast activation protein (FAP) is a type II transmembrane serine protease predominantly expressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment. Fibroblast activation protein (FAP) plays a crucial role in remodeling the extracellular matrix, promoting tumor growth, invasion, and metastasis. It is minimally expressed in normal tissues but significantly upregulated in various cancers, making it a potential biomarker for malignancy.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue sections labeling Fibroblast activation protein, alpha with ab53066 (without peptide-right and with peptide- left).
Blocking buffer: 5% (w/v) non-fat dry milk in TBST.
Primary antibody dilution buffer: 5%(w/v)non-fat dried milk,0.1%(v/v), Tween-20 in TBST.
Secondary antibody dilution buffer: 5%(w/v)non-fat dried milk,0.1%(v/v),Tween-20 in TBST.
12% SDS gel. Nitrocellulose membrane.
Blocking: Room temperature for 2 hours or overnight at 4°C. Then wash 3x for 5 minutes with 0.05% blocking buffer.
Primary antibody incubation: diluted in TBST at 1/500. Incubate overnight with 4 degrees shaking. Then, in 0.05% TBST, wash membrane 3-4 times for 10min.
Secondary antibody incubation: diluted in TBST at 1/2000. Incubate 37°C for 1 hour. Then, in 0.05% TBST, wash membrane 3-4 times for 10min.
ECL development.
All lanes: Western blot - Anti-Fibroblast activation protein, alpha antibody (ab53066) at 1/500 dilution
Lane 1: LOVO cell extract
Lane 2: LOVO cell extract at 40 µg with immunising peptide
Predicted band size: 88 kDa
Observed band size: 90 kDa
Image collected and cropped by CiteAb under a CC-BY license from the publication
Fibroblast activation protein, alpha western blot using anti-Fibroblast activation protein, alpha antibody ab53066. Publication image and figure legend from Evrard, S. M., Lecce, L., et al., 2016, Nat Commun, PubMed 27340017.
ab53066 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab53066 please see the product overview.
Oxidative stress promotes EndMT and has additive effects to TGF-β.(a) Representative dihydroethidium (DHE) microscopy images of thoracic aortic sections from tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE−/− mice after 8 versus 18 weeks HFD demonstrating in situ superoxide production. Analysis by one-way ANOVA; overall P<0.0001. (b) TUNEL assay on atherosclerotic lesions from tamoxifen-induced end.SclCreERT;R26RstopYfp;ApoE−/− mice after 8 versus 18 weeks HFD demonstrating apoptotic Yfp+ cells. For a and b: L=lumen; scale bars, 100 μm. Insets at higher magnification as indicated. Arrows indicate co-positive cells. Staining performed on at least three spatially separated thoracic aortic sections per mouse (n=5 mice per group). Control experiments from non-atherosclerotic mice shown in Supplementary Fig. 8. (c) Phase contrast microscopy of HUVECs grown in basal media (ctrl) or following exposure to TGF-β and/or H2O2 for 5 days. Scale bars, 100 μm. (d) Heatmap showing expression of endothelial genes (top), non-endothelial genes also downregulated in EndMT/EMT, genes known to be upregulated in EndMT/EMT and mesenchymal genes (bottom) for HUVECs exposed to control conditions (basal media—unstimulated), TGF-β or TGF-β plus 200 μM H2O2. Because there are no gene sets for ‘EndMT' or ‘fibroblast' in databases like GO, KEGG, Reactome or MSigDB, this gene list was compiled by extensive literature search (Supplementary Table 2). (e) FAP protein expression by western blot with quantification in HUVECs exposed to control (ctrl) conditions (unstimulated) or TGF-β, with and without H2O2 at 100 or 200 μM. FAP ladder (L) represents 100 kDa (upper) and 75 kDa (lower intense band). FAP expected molecular weight/size is 90 kDa. GAPDH ladder represents 37 kDa. GAPDH expected molecular weight/size is 37 kDa. (f) FAP RNA levels assessed by qRT-PCR under identical conditions. (g) CD31 protein by western blot with quantification. CD31 ladder (L) represents 150 kDa (upper) and 100 kDa (lower intense band). CD31 expected molecular weight/size is 130 kDa. GAPDH ladder represents 37 kDa. GAPDH expected molecular weight/size is 37 kDa. (h) CD31 RNA levels assessed by qRT-PCR is presented for HUVECs under identical conditions. Data in e–h analysed by two-way ANOVA with complete results in Supplementary Table 3. (i) Cell migration for unstimulated HUVECs versus after treatment with TGF-β only or TGF-β+200 μM H2O2 for 5 days. Analysis by one-way ANOVA; overall P=0.015. (j) Cell invasion for unstimulated HUVECs versus after treatment with TGF-β only or TGF-β+200 μM H2O2 for 5 days. Analysis by one-way ANOVA; overall P<0.0001. n=6–9 for qRT-PCR and 3–6 for western blots. Migration and invasion determined from three independent experiments with each experiment having n=3. NS, not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com